English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Kolevská J., M. Svoboda: Evaluation of Pituitary-dependent Hyperadrenocorticism Response to Mitotane Treatment in Dogs. Length of Initial Phase of Treatment in Relation to Initial Value of Urine Cortisol/creatinine Ratio. Acta Vet. Brno 2001, 70: 313-320. The aim of this work was to evaluate the response of dogs with pituitary-dependent hyperadrenocorticism to treatment with mitotane. The relationship between duration of initial phase of therapy and the initial value of urine cortisol/creatinine ratio (UCCR) was studied. All 14 dogs with pituitary-dependent hyperadrenocorticism were treated. Therapeutic protocol of selective adrenocorticolysis was used. The induction dose of mitotane was 25 mg/kg daily. The length of initial phase of therapy was determined individually on the basis of cortisol production changes, which were monitored by immunoreactive cortisol in urine (UCCR) every 2-5 days during the initial phase of treatment. High-dose dexamethasone suppression test was used to differentiate between the pituitary-dependent and adrenal-dependent form of the disease, and the UCCR was measured after dexamethasone suppression. The value of the initial UCCR fluctuated between 58-586 × 10-6, the median of UCCR was 138 × 10-6. Initial phase of therapy lasted 10-64 days. Mean length of initial therapy was 17 days with a median of 14.5 day. The cumulative induction dose of mitotane ranged from 250 to 1600 mg/kg b.w. No linear dependence between the length of initial phase of therapy and the pre-treatment values of UCCR was found by regression and correlation analysis.

acta veterinaria brno

Evaluation of Pituitary-Dependent Hyperadrenocorticism Response to Mitotane Treatment in Dogs. Length of Initial Phase of Treatment in Relation to the Initial Value of Urine Cortisol/Creatinine Ratio